November 30, 2020

The Niche

Knoepfler lab stem cell blog

Lancet

1 min read

For the second year in a row (see awards 2011), Advanced Cell Technology (ACT; stock symbol ACTC) is my stem cell biotech of the year. Their trials for different forms of macular degeneration (here and here and here) are progressing well and as a stem cell scientist I really appreciate the fact they are publishing their data as they go (see their Lancet article here). They are exploring the use of iPS cells for production of platelets as well, which is a very exciting possible …Read More